EUVIMEDOpdag EUVIMED
ÜbersichtsarbeitOpen access · CC BY-NC 4.0

Mantle cell lymphoma—Update on molecular biology, prognostication and treatment approaches

Elisabeth Silkenstedt, Martin Dreyling

Hematological Oncology · 2023-06 · 41 (S1) · 36-42

DOI: 10.1002/hon.3149 ↗

At a glance

Übersichtsarbeit in Hematological Oncology, published online on 2023-06-09. Written by Elisabeth Silkenstedt and 1 co-authors. Institution: Department of Medicine III, LMU University Hospital, Munich, Germany. Major MEDLINE topics: Lymphoma, Mantle-Cell. Cited 67 times so far (Crossref); 41 references. The full text is freely available (open access, CC BY-NC 4.0).

AbstractSubjectsBibliografiske oplysningerCiteRelated studies

Abstract (original language)

Mantle cell lymphoma (MCL) is clinically characterized by its heterogenous behavior with courses ranging from indolent cases that do not require therapy for years to highly aggressive MCL with very limited prognosis. The development and implementation of new targeted and immunotherapeutic approaches have already improved therapeutic options especially for refractory or relapsed disease. Nevertheless, to further optimize MCL treatment, early identification of individual risk profile and risk‐adapted, patient‐tailored choice of therapeutic strategy needs to be prospectively incorporated in clinical patient management. This review summarizes the current knowledge and standard of care regarding biology and clinical management of MCL, highlighting the implementation of new therapeutic approaches especially targeting the immune system.

Subjects

MeSH terms (MEDLINE)

Lymphoma, Mantle-CellAdultHumansPrognosisCombined Modality TherapyAntineoplastic Combined Chemotherapy ProtocolsMolecular Biology

Author keywords

MCLpathogenesisprognosticationtherapy

Authors and institutions

  • Department of Medicine III, LMU University Hospital, Munich, Germany.

Cite

APA

Silkenstedt, E., & Dreyling, M. (2023). Mantle cell lymphoma—Update on molecular biology, prognostication and treatment approaches. Hematological Oncology, 41(S1), 36-42. https://doi.org/10.1002/hon.3149

Vancouver

Silkenstedt E, Dreyling M. Mantle cell lymphoma—Update on molecular biology, prognostication and treatment approaches. Hematological Oncology. 2023;41(S1):36-42. doi:10.1002/hon.3149

BibTeX
@article{Silkenstedt2023,
  author = {Silkenstedt, Elisabeth and Dreyling, Martin},
  title = {Mantle cell lymphoma—Update on molecular biology, prognostication and treatment approaches},
  journal = {Hematological Oncology},
  year = {2023},
  volume = {41},
  number = {S1},
  pages = {36--42},
  doi = {10.1002/hon.3149}
}
Start for free →